Crystalys Raises $130M to Advance Its Gout Drug Through Late-Stage Trials

Crystalys Therapeutics has raised $130 million in a Series B to push its gout drug, dotinurad, through late-stage clinical testing in the United States and Europe.

How the drug works

Dotinurad lowers uric acid by inhibiting URAT1, a transporter protein regulating uric acid levels. Elevated uric acid is the underlying driver of gout, a painful and increasingly common form of inflammatory arthritis.

URAT1 sits in the kidney tubules and reabsorbs uric acid from urine back into the blood. That reabsorption is substantial — most of the uric acid filtered by the kidney is recovered rather than excreted — so blocking the transporter increases how much is lost in urine.

The distinction from the standard treatment matters. Allopurinol works at the other end, inhibiting the enzyme that produces uric acid in the first place. Dotinurad does not reduce production; it increases elimination.

That has a practical consequence worth noting: a uricosuric drug raises uric acid concentration in urine, which can promote kidney stone formation in susceptible patients — a limitation this class has historically carried.

Why gout is undertreated

Gout occurs when uric acid exceeds its solubility and crystallises in joints, provoking intense inflammation. Attacks are excruciating and resolve, which shapes how the disease is managed badly.

Because attacks resolve, patients and clinicians frequently treat the episode rather than the underlying uric acid level. Long-term therapy requires taking a drug daily during periods when nothing hurts, and adherence is poor.

Dosing is also frequently inadequate. Allopurinol works when titrated to a target uric acid level, and it is commonly left at a starting dose that does not reach it — so the drug is blamed for failing when it was never given properly.

Untreated, crystals accumulate into deposits that damage joints permanently and cause chronic pain rather than episodic attacks.

A drug with a track record abroad

Dotinurad was discovered by Japanese drugmaker Fuji Yakuhin and approved in Japan in 2020, with subsequent clearances in China, the Philippines and Thailand. Crystalys acquired US and European rights in 2024.

It would compete with long-standing options such as allopurinol and Amgen’s Krystexxa.

Those two occupy opposite ends. Allopurinol is cheap, oral and first-line. Krystexxa is an infused enzyme that breaks uric acid down directly, reserved for severe refractory disease and carrying infusion reactions and immunogenicity problems.

The space between them — an oral option for patients allopurinol does not control or who cannot tolerate it — is where a URAT1 inhibitor would sit.

The de-risked strategy

“This financing strengthens our ability to advance our trials and positions Crystalys to achieve multiple important clinical and regulatory milestones,” said chief executive James Mackay.

The round drew a deep syndicate, led by Frazier Life Sciences and joined by Wellington Management, Cormorant Asset Management, SR One, Novo Holdings and more than 20 additional firms.

Backing a drug approved elsewhere is comparatively de-risked: the science is established, and the task is confirming it for Western regulators.

Why gout is becoming more common

Incidence has risen in most high-income countries over recent decades, and the reasons are largely the same ones driving metabolic disease generally.

Obesity increases uric acid production and reduces its excretion. Insulin resistance directly promotes renal reabsorption of urate, which is why gout clusters with diabetes and metabolic syndrome rather than occurring independently. Kidney disease reduces clearance.

Diet contributes and less than the folklore suggests. Purine-rich foods raise uric acid modestly; fructose does so more, through a metabolic pathway that consumes ATP and generates urate as a byproduct, which places sweetened drinks higher on the list than the traditional emphasis on red meat and shellfish implies.

Medications matter too. Thiazide diuretics and low-dose aspirin both reduce uric acid excretion, and both are widely prescribed in exactly the older population where gout is most common.

The ageing population compounds all of it. Gout is largely a disease of later life in men and postmenopausal women, and demographic change alone would raise prevalence without any other factor shifting.

What the trials will have to show

The endpoint in gout drug development is unusually clean, which is part of why the path is considered de-risked.

Regulators accept serum uric acid below a defined threshold as the primary measure, because the relationship between concentration and crystal formation is physical chemistry rather than biology. Below the solubility limit, existing crystals dissolve and new ones do not form.

That makes the trial short and the readout unambiguous compared with most inflammatory disease, where endpoints are composite scores of symptoms and function.

What a surrogate cannot settle is whether patients feel better, and the connection is not immediate. Dissolving accumulated deposits takes months to years, and paradoxically lowering uric acid can trigger attacks initially as crystals mobilise — which is why treatment usually begins alongside anti-inflammatory cover, and why patients who are not warned frequently stop the drug believing it made them worse.

The residual risk is that approval elsewhere does not transfer. Regulators expect trials including their own populations, and uric acid handling varies genetically between populations — variants affecting urate transporters differ in frequency between East Asian and European ancestry groups, which is a real reason a uricosuric drug might perform differently. Business news, not medical advice.